Abstract:Integrin alpha(v)beta(6) is overexpressed in a variety of cancers, and its expression is often associated with poor prognosis. Therefore, there is a need to develop affinity reagents for noninvasive imaging of integrin alpha(v)beta(6) expression since it may provide early cancer diagnosis, more accurate prognosis, and better treatment planning. We recently engineered and validated highly stable cystine knot peptides that selectively bind integrin alpha(v)beta(6) with no cross-reactivity to integrins alpha(v)beta(5), alpha(5)beta(1), or alpha(v)beta(3), also known to be overexpressed in many cancers. Here, we developed a single photon emission computed tomography (SPECT) probe for imaging integrin alpha(v)beta(6) positive tumors. Cystine knot peptide, S(0)2, was first conjugated with a single amino acid chelate (SAAC) and labeled with [Tc-99m(H2O)(3)(CO)(3)](+). The resulting probe, Tc-99m-SAAC-S(0)2, was then evaluated by in vitro cell uptake studies using two alpha(v)beta(6) positive cell lines (human lung adenocarcinoma cell line HCC4006 and pancreatic cancer cell line BxPC-3) and two alpha(v)beta(6) negative cell lines (human lung adenocarcinoma cell line H838 and human embryonic kidney cell line 293T). Next, SPECT/CT and biodistribution studies were performed in nude mice bearing HCC4006 and H838 tumor xenografts to evaluate the in vivo performance of Tc-99m-SAAC-S(0)2. Significant differences in the uptake of Tc-99m-SAAC-S(0)2 were observed in alpha(v)beta(6) positive vs negative cells (P < 0.05). Biodistribution and small animal SPECT/CT studies revealed that Tc-99m-SAAC-S(0)2 accumulated to moderate levels in antigen positive tumors (similar to 2% ID/g at 1 and 6 h postinjection, n = 3 or 4/group). Moreover, the probe demonstrated tumor-to-background tissue ratios of 6.81 +/- 2.32 (tumor-to-muscle) and 1.63 +/- 0.18 (tumor-to-blood) at 6 h postinjection in alpha(v)beta(6) positive tumor xenografts. Co-incubation of the probe with excess amount of unlabeled S(0)2 as a blocking agent demonstrated significantly reduced tumor uptake, which is consistent with specific binding to the target. Renal filtration was the main route of clearance. In conclusion, knottin peptides are excellent scaffolds for which to develop highly stable imaging probes for a variety of oncological targets. Tc-99m-SAAC-S(0)2 demonstrates promise for use as a SPECT agent to image integrin alpha(v)beta(6) expression in living systems.

Tc-99m-Cyclopentadienyl Tricarbonyl Chelate-Labeled Compounds As Selective Sigma-2 Receptor Ligands For Tumor Imaging

Synthesis and Biological Evaluation of a Novel 99mtc Cyclopentadienyl Tricarbonyl Complex ([(Cp-R)99mtc(co)3]) for Sigma-2 Receptor Tumor Imaging

Novel cyclopentadienyl tricarbonyl (99m)tc complexes containing 1-piperonylpiperazine moiety: potential imaging probes for sigma-1 receptors.

Development of a Highly Specific 18 F-Labeled Radioligand for Imaging of the Sigma-2 Receptor in Brain Tumors

Design and Investigation of a [18F]-Labeled Benzamide Derivative as a High Affinity Dual Sigma Receptor Subtype Radioligand for Prostate Tumor Imaging.

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.

Tc-99m-Labeled Cystine Knot Peptide Targeting Integrin Alpha(V)Beta(6) For Tumor Spect Imaging

Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.

eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors

Cyclic-Arginine-Glycine-Aspartic (C-Rgd) Conjugated Polymeric Micelles for SPECT/NIRF Dual-Modality Tumor Imaging

Design, development and bio-evaluation of a novel radio-ligand 99mTc-THQ-DTPA as a sigma 2 receptor specific breast tumor imaging agent

99mTc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3 Expression

<sup>99m</sup>Tc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin α<sub>v</sub>β<sub>3</sub>Expression

An Integrin Alpha 6-Targeted Radiotracer with Improved Receptor Binding Affinity and Tumor Uptake

(99M)tc-Labeled Dimeric Octreotide Peptide: a Radiotracer with High Tumor Uptake for Single-Photon Emission Computed Tomography Imaging of Somatostatin Receptor Subtype 2-Positive Tumors.

Technetium-99m- Arg-Arg-Leu(g2), a Modified Peptide Probe Targeted to Neovascularization in Molecular Tumor Imaging.

Synthesis and Initial in Vivo Evaluation of A Radiofluorinated Sigma Receptor Radioligand for Prostate Tumor Imaging

Design and Synthesis of 111In-Ccpm-rgd Nanoparticles for Dual-modality Molecular Imaging

Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.

Evaluation of<sup>111</sup>In-Labeled Cyclic RGD Peptides: Tetrameric not Tetravalent